ProCE Banner Activity

CME

New Approaches to Optimize Asparaginase Therapy in the Management of Acute Lymphoblastic Leukemia

Multimedia
In this on-demand webcast from a live symposium, oncology experts Daniel J. DeAngelo, MD, Emily Curran, MD, and Kjeld Schmiegelow, MD, discuss the latest evidence to optimize the care of AYA and adult patients with acute lymphoblastic leukemia using asparaginase-based therapies.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 07, 2022

Expiration: June 06, 2023

No longer available for credit.

Share

Faculty

Emily Curran

Emily Curran, MD

Assistant Professor
Department of Internal Medicine
Division of Hematology and Oncology
University of Cincinnati Cancer Center
Cincinnati, Ohio

Daniel J. DeAngelo

Daniel J. DeAngelo, MD, PhD

Professor of Medicine
Harvard Medical School
Chief, Division of Leukemia
Dana-Farber Cancer Institute
Boston, Massachusetts

Kjeld Schmiegelow

Kjeld Schmiegelow, MD, DMSci

Professor
Department of Pediatric Oncology
Righospitalet University Hospital
Copenhagen, Denmark

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Jazz Pharmaceuticals, Inc.

Target Audience

This program is intended for physicians and other healthcare professionals who care for adolescent/young adult and adult patients with acute lymphoblastic leukemia.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select optimal asparaginase-containing regimens for adolescent/young adult and adult patients with ALL based on clinical data and expert recommendations
  • Identify optimal methods of measuring and monitoring subclinical hypersensitivity or silent inactivation
  • Implement optimal approaches to achieve continued and active asparaginase treatment, including activity level testing and premedication
  • Integrate newly approved dosing schedules or recombinant asparaginase formulations when considering asparaginase reexposure of asparaginase treatments in adolescent/young adult and adult patients with ALL
  • Discuss recent clinical evidence and current recommendations for optimizing the therapeutic regimens for AYA ALL patients with pediatric-inspired protocols

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Daniel J. DeAngelo, MD, PhD

Professor of Medicine
Harvard Medical School
Chief, Division of Leukemia
Dana-Farber Cancer Institute
Boston, Massachusetts

Daniel J. DeAngelo, MD, PhD, has disclosed that he has received funds for research support from AbbVie, Blueprint, GlycoMimetics, and Novartis; consultant/advisor/speaker fees from AbbVie, Agios, Amgen, Autolus, Blueprint, Forty-Seven, Gilead, GlycoMimetics, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, and Takeda; and was on the DSMB for Daiichi-Sanko and Fibrogen.

Faculty Disclosure

Primary Author

Emily Curran, MD

Assistant Professor
Department of Internal Medicine
Division of Hematology and Oncology
University of Cincinnati Cancer Center
Cincinnati, Ohio

Emily Curran, MD, has disclosed that she has received consulting/advisor/speaker fees from Amgen, Incyte, Kite, Pfizer, Servier, and Tempus.

Kjeld Schmiegelow, MD, DMSci

Professor
Department of Pediatric Oncology
Righospitalet University Hospital
Copenhagen, Denmark

Kjeld Schmiegelow, MD, has disclosed that he has received consulting/advisor/speaker fees from Jazz Pharmaceuticals and Servier.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Lisa Kuhns, PhD

Lisa Kuhns has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 07, 2022, through June 06, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge and competence of learners in integrating the latest data and strategies into treatment plans for patients with acute lymphoblastic leukemia.